287 related articles for article (PubMed ID: 32523115)
1. Cytokines that target immune killer cells against tumors.
Qiao J; Fu YX
Cell Mol Immunol; 2020 Jul; 17(7):722-727. PubMed ID: 32523115
[TBL] [Abstract][Full Text] [Related]
2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
3. Next-generation cytokines for cancer immunotherapy.
Xue D; Hsu E; Fu YX; Peng H
Antib Ther; 2021 Apr; 4(2):123-133. PubMed ID: 34263141
[TBL] [Abstract][Full Text] [Related]
4. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
5. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
6. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
7. IL-21: a pleiotropic cytokine with potential applications in oncology.
Croce M; Rigo V; Ferrini S
J Immunol Res; 2015; 2015():696578. PubMed ID: 25961061
[TBL] [Abstract][Full Text] [Related]
8. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
Phung CD; Tran TH; Kim JO
Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
[TBL] [Abstract][Full Text] [Related]
9. The potential and promise of IL-15 in immuno-oncogenic therapies.
Robinson TO; Schluns KS
Immunol Lett; 2017 Oct; 190():159-168. PubMed ID: 28823521
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells: Development, Maturation, and Clinical Utilization.
Abel AM; Yang C; Thakar MS; Malarkannan S
Front Immunol; 2018; 9():1869. PubMed ID: 30150991
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of cancer by IL-12-based cytokine combinations.
Weiss JM; Subleski JJ; Wigginton JM; Wiltrout RH
Expert Opin Biol Ther; 2007 Nov; 7(11):1705-21. PubMed ID: 17961093
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
14. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.
Fewkes NM; Mackall CL
Cancer J; 2010; 16(4):392-8. PubMed ID: 20693852
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
16. Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells.
Ghofrani J; Lucar O; Dugan H; Reeves RK; Jost S
Eur J Immunol; 2019 Aug; 49(8):1153-1166. PubMed ID: 31016720
[TBL] [Abstract][Full Text] [Related]
17. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
18. The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.
Eriksen KW; Søndergaard H; Woetmann A; Krejsgaard T; Skak K; Geisler C; Wasik MA; Odum N
Mol Immunol; 2009 Feb; 46(5):812-20. PubMed ID: 18947877
[TBL] [Abstract][Full Text] [Related]
19. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15: new kid on the block for antitumor combination therapy.
Van den Bergh JM; Van Tendeloo VF; Smits EL
Cytokine Growth Factor Rev; 2015 Feb; 26(1):15-24. PubMed ID: 25306466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
